Newark, Calif.-based Incarda Therapeutics Inc., a company developing an inhaled therapy for recent-onset paroxysmal atrial fibrillation (PAF), has closed a $42 million series B financing. Proceeds from the round will be used primarily to fund the company's recently initiated phase II study of Inrhythm, an inhaled flecainide drug-device combo. Results from the study will be available in the second half of 2019, Incarda's president and CEO, Grace Colón, told BioWorld.